SCHEMBL5541360

SCHEMBL5541360

CC1Cc2cc([O])ccc2O1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.60
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
KDM4E B2RXH2 3/20 0.44
PBRM1 Q86U86 1/20 0.44
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
CYP11B2 P19099 2/20 0.42
BRD4 O60885 3/20 0.41
CREBBP Q92793 3/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547658 0.85 ALDH1A1 (0.47) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL15667344 0.78 TDP1 (0.57) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL318360 0.78 TDP1 (0.57) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL15667383 0.78 TDP1 (0.57) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL5541364 0.77 TDP1 (0.60) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL16178935 0.77 TDP1 (0.56) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL5809100 0.77 PBRM1 (0.60) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL15724653 0.77 TDP1 (0.56) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL15749929 0.77 TDP1 (0.56) TDP1ALDH1A1GAASMN1; SMN2RAB9A
SCHEMBL15724650 0.77 TDP1 (0.56) TDP1ALDH1A1GAASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TDP1 4666/4885ALDH1A1 355/4885GAA 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.